GLP-1 Receptor Agonists: Metabolic Effects and Their Role in Managing T2DM

Format: Webinar

Credit(s): 1.00 (60 min)

Webinar Date(s):

Friday, January 13, 2023 12:30 - 1:30 PM CT
Monday, January 26, 2023 7:00 - 8:00 PM CT

Credit Type(s):

Physicians – AMA PRA Category 1 Credit(s) ™
Physicians – prescribed AAFP Credit(s)
Physicians/ABIM MOC – ABIM MOC Point(s)
Physician Assistants – AAPA Category 1 CME
Nurse Practitioners – contact hour(s) of continuing education

PROGRAM OVERVIEW

In T2DM there is a combination of reduced insulin production and secretion and insulin resistance. One cause of decreased insulin secretion is an impaired response to glucose-stimulated release of glucagon-like peptide 1 (GLP-1). Endogenous GLP-1 has multiple physiologic effects but is short-lived. GLP-1 receptor analogues (RAs) have a longer half-life, retain bioactivity, and have benefits beyond glycemic management, including mediating satiety; causing weight loss; and favorable cardiovascular, hepatic, and renal effects.

Based on the wide-ranging beneficial effects of GLP-1 RAs, the management of T2DM is no longer based on glucose control alone. The most recent ADA guidelines for T2DM provide guidance on drug- and patient-specific factors to consider when selecting an antihyperglycemic agent and therapeutic algorithms that center on a patient’s cardiovascular and renal profiles.

GLP-1 Receptor Agonists: Metabolic Effects and Their Role in Managing T2DM will inform clinicians about the pleiotropic effects of GLP-1 RAs, the demonstrated clinical efficacy of these agents for managing patients with T2DM and a variety of comorbid conditions, and guideline recommendations for incorporating GLP-1 RAs into management strategies for T2DM.